Knut S.
- Country
- Germany
- Department
- Hautklinik
Research Overview
- A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study)
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic Dermographism
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa
Data & Insights
Has run more than one trial at 253 of 544 partner sites.
Specializations
Inflammatory Skin Conditions
The investigator specializes in treating moderate to severe atopic dermatitis, conducting extensive research into novel therapeutic approaches for this chronic skin condition. Their work encompasses evaluating various treatment modalities, including topical corticosteroids and innovative biological therapies.
- Atopic Dermatitis Management
- Biological Therapy Assessment
- Long-term Treatment Strategies
Chronic Urticaria Research
Focused on investigating treatments for chronic spontaneous urticaria and chronic inducible urticaria. The investigator studies innovative therapeutic approaches for patients who show inadequate response to conventional treatments.
- Antihistamine-Resistant Cases
- Novel Treatment Protocols
- Urticaria Control Assessment
Complex Dermatological Disorders
Expertise extends to treating hidradenitis suppurativa and plaque psoriasis. The investigator evaluates emerging therapies for these challenging conditions, with particular attention to Netherton syndrome and other rare skin disorders.
- Inflammatory Lesion Management
- Rare Skin Disease Treatment
- Clinical Response Evaluation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.